MSCs (mesenchymal stem cells)have an immunomodulatory effect in the treatment of Crohn’s disease. This means that they can regulate the immune system to reduce inflammation in the intestines and promote tissue repair.
MSCs are thought to work by releasing molecules that interact with immune cells and inhibit the inflammatory response. They can reduce the production of pro-inflammatory cytokines, which are signalling molecules that trigger inflammation in the intestines. MSCs also induce the production of anti-inflammatory cytokines, which help to dampen the immune response.
In Crohn’s disease, the immune system attacks the lining of the digestive tract, leading to inflammation and damage. MSCs have been shown to suppress the activity of immune cells that are involved in this process, such as T cells and dendritic cells. They can also promote the activity of regulatory T cells, which help to prevent excessive immune activation and inflammation.
In addition, MSCs have been shown to promote tissue repair by enhancing the growth and differentiation of intestinal epithelial cells. This can help to restore the integrity of the intestinal lining and reduce the risk of complications such as fistulas and strictures.
Overall, MSC immunomodulation is the best approach to the treatment of Crohn’s disease, as it targets the underlying immune dysfunction and inflammation that drive the disease. The best part is that these results don’t just cover the symptoms temporarily but seem to be truly reprogramming the immune system for long term results.
